MutationSymbol,MutationGeneID,RegulatorSymbol,RegulonRegulator,RegulatorType,Regulon,MutationRegulatorEdge,MutationRegulonEdge,SpearmanCorrelationTFAndEigenGene,RMST_diff_UnderActiveMinusOverActiveMGMTUnMeth,RMST_diff_UnderActiveMinusOverActiveMGMTMeth,Cox_HR_Training,IfCancerDriverMutation,IfDETFForTCGAGBM,IfCRISPR-Cas9SignificantTF,RNAiTFGeneEssentialityAchilles,Drug,DrugMechOfAction,TargetSymbol,DrugTarget,Miner_Target_Type,DrugTrialPhaseGBM,Cancer_PhaseIV
ATRX,ENSG00000085224,hsa-mir-20b,hsa-mir-20b,miRNA,2388,1,-7.287713237,-0.377067606,530.0752137,-131,3.525170683,yes,#N/A,#N/A,,CAFFEINE,Adenosine receptor antagonist,ADORA1,ENSG00000163485,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ELF1,ENSG00000120690,TF,519,-1,-3.243824198,0.408372024,334.2444444,387.6666667,2.516789636,,yes,#N/A,-0.057585056,CAFFEINE,Adenosine receptor antagonist,ADORA1,ENSG00000163485,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,ELF1,ENSG00000120690,TF,519,-1,-4.31670568,0.408372024,334.2444444,387.6666667,2.516789636,,yes,#N/A,-0.057585056,CAFFEINE,Adenosine receptor antagonist,ADORA1,ENSG00000163485,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,519,-1,-6.650590276,0.408372024,334.2444444,387.6666667,2.516789636,yes,yes,#N/A,-0.057585056,CAFFEINE,Adenosine receptor antagonist,ADORA1,ENSG00000163485,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,416,-1,-2.689790982,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,416,-1,-2.689790982,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,416,-1,-6.099677054,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,416,-1,-6.099677054,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,Phase 1,#N/A
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,416,1,2.358603796,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,416,1,2.358603796,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,416,1,4.46190652,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,416,1,4.46190652,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,ADORA2B,ENSG00000170425,RegulonGene,Phase 1,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CAFFEINE,Adenosine receptor antagonist,ADORA3,ENSG00000282608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,DOBUTAMINE,Beta-2 adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,EPHEDRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,EPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,NOREPINEPHRINE,Adrenergic receptor agonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,PROPRANOLOL,Beta-2 adrenergic receptor antagonist,ADRB2,ENSG00000169252,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,CARVEDILOL,Adrenergic receptor beta antagonist,ADRB2,ENSG00000169252,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,IBRUTINIB,Tyrosine-protein kinase BTK inhibitor,BTK,ENSG00000010671,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1638,-1,-5.283671066,0.490108127,282.0390396,138.2222222,2.717098111,yes,yes,#N/A,-0.147069167,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,405,-1,-7.644356643,0.438395898,302.5435897,293.9666667,3.081648636,yes,#N/A,yes,-0.032298401,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1638,-1,-7.304272808,0.490108127,282.0390396,138.2222222,2.717098111,yes,yes,#N/A,-0.147069167,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,GATA2,ENSG00000179348,TF,1977,1,-3.909553681,-0.312140047,254.502439,-80.17482517,2.386896437,,#N/A,#N/A,-0.016930102,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,GATA2,ENSG00000179348,TF,1977,1,-6.517212167,-0.312140047,254.502439,-80.17482517,2.386896437,yes,#N/A,#N/A,-0.016930102,TOPIRAMATE,Carbonic anhydrase II inhibitor,CA2,ENSG00000104267,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,GEMTUZUMAB,Myeloid cell surface antigen CD33 binding agent,CD33,ENSG00000105383,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF4,ENSG00000196628,TF,734,1,-2.293281098,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF4,ENSG00000196628,TF,734,1,-2.270643248,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TCF4,ENSG00000196628,TF,734,1,-2.498994021,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ABATACEPT,T-lymphocyte activation antigen CD86 inhibitor,CD86,ENSG00000114013,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1569,1,3.039118543,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1569,1,3.039118543,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1569,1,3.039118543,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1569,1,3.271856436,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1569,1,3.271856436,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1569,1,3.271856436,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SATB1,ENSG00000182568,TF,1569,-1,-4.343950746,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SATB1,ENSG00000182568,TF,1569,-1,-4.343950746,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SATB1,ENSG00000182568,TF,1569,-1,-4.343950746,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1569,1,3.24921744,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1569,1,3.24921744,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1569,1,3.24921744,0.650296832,-489.3333333,-245.8333333,-2.004309389,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK4,ENSG00000135446,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1560,1,-5.837271897,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1560,1,-5.837271897,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1653,-1,-6.284755928,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1653,-1,-6.284755928,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1560,1,-5.837271897,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1653,-1,-6.284755928,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1560,1,-8.900132775,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1560,1,-8.900132775,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1653,-1,-8.229076699,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1653,-1,-8.229076699,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1560,1,-8.900132775,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1653,-1,-8.229076699,0.413115929,819.521164,420.1714286,2.792753994,yes,yes,#N/A,-0.147069167,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1560,1,-4.100022768,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,ABEMACICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1560,1,-4.100022768,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,PALBOCICLIB,Cyclin-dependent kinase 4/cyclin D1 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1560,1,-4.100022768,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,RIBOCICLIB,Cyclin-dependent kinase 4 inhibitor,CDK6,ENSG00000105810,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1638,-1,-5.283671066,0.490108127,282.0390396,138.2222222,2.717098111,yes,yes,#N/A,-0.147069167,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1638,-1,-7.304272808,0.490108127,282.0390396,138.2222222,2.717098111,yes,yes,#N/A,-0.147069167,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,439,-1,-6.010206319,0.446212619,275.2397177,143.4923077,3.061868333,yes,yes,#N/A,0.043239717,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ROCURONIUM,Muscle-type nicotinic acetylcholine receptor antagonist,CHRNB1,ENSG00000170175,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF4,ENSG00000196628,TF,734,1,-2.293281098,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SREBF1,ENSG00000072310,TF,281,-1,-2.432672531,0.324370727,357.9166667,35.70238095,2.33286947,yes,#N/A,#N/A,-0.090115373,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT6,ENSG00000166888,TF,59,-1,-2.265956377,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF4,ENSG00000196628,TF,734,1,-2.270643248,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SREBF1,ENSG00000072310,TF,281,-1,-2.440443847,0.324370727,357.9166667,35.70238095,2.33286947,yes,#N/A,#N/A,-0.090115373,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT6,ENSG00000166888,TF,59,-1,-2.232710956,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT6,ENSG00000166888,TF,59,1,2.53110771,0.66222257,456.3642241,-57.08571429,2.376773204,yes,yes,#N/A,-0.01265308,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TCF4,ENSG00000196628,TF,734,1,-2.498994021,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SREBF1,ENSG00000072310,TF,281,-1,-2.666923547,0.324370727,357.9166667,35.70238095,2.33286947,yes,#N/A,#N/A,-0.090115373,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PEGFILGRASTIM,Granulocyte colony stimulating factor receptor agonist,CSF3R,ENSG00000119535,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ARID5A,ENSG00000196843,TF,127,-1,-3.119804505,0.558941883,294.05,-195,2.399477709,yes,#N/A,#N/A,0.080033004,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2052,-1,-2.381727672,0.557897827,321.1333333,-669.2,2.468514001,yes,#N/A,#N/A,-0.112566588,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,422,-1,-4.207363504,0.716310266,402.6923077,-158,2.743655288,,#N/A,yes,-0.032298401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,422,-1,-2.646123445,0.716310266,402.6923077,-158,2.743655288,yes,#N/A,yes,-0.032298401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,ARID5A,ENSG00000196843,TF,127,-1,-2.93041491,0.558941883,294.05,-195,2.399477709,yes,#N/A,#N/A,0.080033004,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,422,1,2.351765615,0.716310266,402.6923077,-158,2.743655288,,#N/A,yes,-0.032298401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,127,-1,-2.104594288,0.558941883,294.05,-195,2.399477709,yes,#N/A,#N/A,0.080033004,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,DDR2,ENSG00000162733,RegulonGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,CETUXIMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Early Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,OSIMERTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,PANITUMUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,ERLOTINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,GEFITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,NIMOTUZUMAB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,EPITINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 1,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 2,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1560,-1,2.205229764,-0.366579749,667.6038961,441.275,2.551675906,yes,yes,yes,0.009674745,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1570,-1,-2.086584087,0.753422024,-189.7184265,370.6388889,-2.436584784,yes,yes,yes,0.009674745,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,EMX2,ENSG00000170370,TF,3675,1,3.022872429,0.416164881,339.8987854,348.7142857,2.785726712,yes,yes,#N/A,-0.077155298,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2528,1,1.974430777,0.678137178,556.0197343,268.9553571,3.459880826,yes,#N/A,#N/A,-0.00778872,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,NR2E1,ENSG00000112333,TF,2523,1,-2.250201872,-0.46820395,-265.3392857,256.2596154,-2.078553831,yes,#N/A,#N/A,-0.00778872,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2830,1,3.522346586,0.7517377,286.1,246.9285714,2.69241926,yes,#N/A,#N/A,-0.107024401,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SOX15,ENSG00000129194,TF,1482,1,2.514898753,0.434594365,172.0609562,157.5512821,2.213392769,yes,#N/A,#N/A,,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,IRF3,ENSG00000126456,TF,2823,1,2.216935554,0.433478826,181.2239258,133.0416667,2.01456046,yes,#N/A,#N/A,-0.107024401,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,ZNF589,ENSG00000164048,TF,1545,-1,-2.240153136,0.363584081,-831.0620915,125.4166667,-4.393614322,yes,#N/A,#N/A,0.145774197,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1163,-1,-2.161810436,0.392741256,-318.7992424,-117.3730769,-3.197740567,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2604,1,2.175532782,0.706229399,365.1642857,-185.6666667,4.201920634,yes,#N/A,yes,0.102423629,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,RFX2,ENSG00000087903,TF,2597,1,2.040466804,0.649985202,127.0852273,-216.0222222,2.134615453,yes,#N/A,yes,0.102423629,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,LTF,ENSG00000012223,TF,1519,1,-2.243690693,-0.409178276,-821.8928571,-272.2333333,-4.382025373,yes,#N/A,#N/A,-0.11761407,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1173,-1,-1.982428779,0.706238859,-481.2571429,-335.8928571,-2.980020556,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1559,-1,-2.076037258,0.651796193,-182.6439394,-403.6333333,-3.13501711,yes,yes,yes,0.009674745,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
EGFR,ENSG00000146648,SOX9,ENSG00000125398,TF,1398,1,-2.995503365,-0.478372432,-336.6666667,-557.725,-2.914680408,yes,yes,#N/A,-0.025269831,VANDETANIB,Epidermal growth factor receptor inhibitor,EGFR,ENSG00000146648,MutationGene,Phase 3,#N/A
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,236,-1,-5.881277643,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,236,-1,-5.881277643,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
GPR98,,JUN,ENSG00000177606,TF,236,-1,-5.371566811,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,JUN,ENSG00000177606,TF,236,-1,-5.371566811,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
HMCN1,ENSG00000143341,JUN,ENSG00000177606,TF,236,1,2.253516612,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
HMCN1,ENSG00000143341,JUN,ENSG00000177606,TF,236,1,2.253516612,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,236,-1,-12.06295946,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,236,-1,-12.06295946,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,236,1,4.427184185,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,236,1,4.427184185,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,JUN,ENSG00000177606,TF,236,-1,-3.574024907,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,JUN,ENSG00000177606,TF,236,-1,-3.574024907,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,JUN,ENSG00000177606,TF,236,-1,-3.903924703,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,DASATINIB,Ephrin type-A receptor 2 inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,JUN,ENSG00000177606,TF,236,-1,-3.903924703,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHA2,ENSG00000142627,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB1,ENSG00000154928,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB1,ENSG00000154928,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB1,ENSG00000154928,RegulonGene,Phase 3,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB1,ENSG00000154928,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB1,ENSG00000154928,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB2,ENSG00000133216,RegulonGene,Phase 3,#N/A
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB2,ENSG00000133216,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB2,ENSG00000133216,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB2,ENSG00000133216,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,236,-1,-5.881277643,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,236,-1,-5.881277643,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
GPR98,,JUN,ENSG00000177606,TF,236,-1,-5.371566811,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
GPR98,,JUN,ENSG00000177606,TF,236,-1,-5.371566811,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
HMCN1,ENSG00000143341,JUN,ENSG00000177606,TF,236,1,2.253516612,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
HMCN1,ENSG00000143341,JUN,ENSG00000177606,TF,236,1,2.253516612,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,236,-1,-12.06295946,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,236,-1,-12.06295946,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,236,1,4.427184185,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,236,1,4.427184185,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,JUN,ENSG00000177606,TF,236,-1,-3.574024907,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,JUN,ENSG00000177606,TF,236,-1,-3.574024907,0.561847921,184.3976564,353.624183,2.830634967,,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,JUN,ENSG00000177606,TF,236,-1,-3.903924703,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,JUN,ENSG00000177606,TF,236,-1,-3.903924703,0.561847921,184.3976564,353.624183,2.830634967,yes,#N/A,#N/A,-0.209271379,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,EPHB4,ENSG00000196411,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SMAD3,ENSG00000166949,TF,3018,-1,-6.889241371,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1707,-1,-6.798971845,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SP4,ENSG00000105866,TF,1574,1,-6.892565053,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
GPR98,,ZNF217,ENSG00000171940,TF,3008,-1,-3.842626506,0.785950115,380.2865497,655.3047619,3.323629463,,yes,yes,-0.050900246,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
GPR98,,SMAD1,ENSG00000170365,TF,1707,-1,-3.370103078,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD3,ENSG00000166949,TF,3018,-1,-11.01853724,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1707,-1,-13.2131381,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SP4,ENSG00000105866,TF,1574,1,-11.40938808,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,ZNF217,ENSG00000171940,TF,3008,1,2.875243705,0.785950115,380.2865497,655.3047619,3.323629463,yes,yes,yes,-0.050900246,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SMAD3,ENSG00000166949,TF,3018,1,3.551596255,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SP4,ENSG00000105866,TF,1574,-1,3.578678744,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD3,ENSG00000166949,TF,3018,-1,-3.788104834,0.492466175,12.43571429,449.8763736,2.387661851,,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1707,-1,-3.865292894,0.393197642,219.0872093,435.2916667,2.982083829,,yes,#N/A,0.003597326,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
SEMA3C,ENSG00000075223,SP4,ENSG00000105866,TF,1574,1,-3.574070003,-0.313601712,139.5117581,349.0333333,2.770193154,,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,AFATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,LAPATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,DACOMITINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,PERTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TRASTUZUMAB,Receptor protein-tyrosine kinase erbB-2 inhibitor,ERBB2,ENSG00000141736,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,NERATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,TESEVATINIB,Epidermal growth factor receptor erbB1 inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD3,ENSG00000166949,TF,3018,-1,-4.15408969,0.492466175,12.43571429,449.8763736,2.387661851,yes,#N/A,#N/A,0.048050422,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1707,-1,-5.045414645,0.393197642,219.0872093,435.2916667,2.982083829,yes,yes,#N/A,0.003597326,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SP4,ENSG00000105866,TF,1574,1,-4.657534739,-0.313601712,139.5117581,349.0333333,2.770193154,yes,#N/A,#N/A,-0.047921097,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB2,ENSG00000141736,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB3,ENSG00000065361,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB3,ENSG00000065361,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB3,ENSG00000065361,RegulonGene,Phase 3,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB3,ENSG00000065361,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VANDETANIB,Epidermal growth factor receptor inhibitor,ERBB3,ENSG00000065361,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,37,-1,-3.881340746,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,37,-1,-3.881340746,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,37,-1,-3.881340746,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,MAX,ENSG00000125952,TF,1307,-1,-4.025498363,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,MAX,ENSG00000125952,TF,1307,-1,-4.025498363,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,MAX,ENSG00000125952,TF,1307,-1,-4.025498363,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
DNAH5,ENSG00000039139,BCL6,ENSG00000113916,TF,1523,1,2.159430899,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
DNAH5,ENSG00000039139,BCL6,ENSG00000113916,TF,1523,1,2.159430899,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
DNAH5,ENSG00000039139,BCL6,ENSG00000113916,TF,1523,1,2.159430899,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,MTF1,ENSG00000188786,TF,677,-1,-5.120396613,0.375173629,386.431085,235.1203704,3.650042175,,#N/A,yes,0.032928344,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,MTF1,ENSG00000188786,TF,677,-1,-5.120396613,0.375173629,386.431085,235.1203704,3.650042175,,#N/A,yes,0.032928344,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,MTF1,ENSG00000188786,TF,677,-1,-5.120396613,0.375173629,386.431085,235.1203704,3.650042175,,#N/A,yes,0.032928344,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BCL6,ENSG00000113916,TF,1523,-1,-4.851964641,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BCL6,ENSG00000113916,TF,1523,-1,-4.851964641,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BCL6,ENSG00000113916,TF,1523,-1,-4.851964641,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,538,-1,-5.761883443,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,538,-1,-5.761883443,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,538,-1,-5.761883443,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,37,-1,-8.503373505,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,37,-1,-8.503373505,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,37,-1,-8.503373505,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,MAX,ENSG00000125952,TF,1307,-1,-7.663318703,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,MAX,ENSG00000125952,TF,1307,-1,-7.663318703,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,MAX,ENSG00000125952,TF,1307,-1,-7.663318703,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAX,ENSG00000125952,TF,1307,1,4.095038391,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAX,ENSG00000125952,TF,1307,1,4.095038391,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAX,ENSG00000125952,TF,1307,1,4.095038391,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,677,1,4.375581069,0.375173629,386.431085,235.1203704,3.650042175,yes,#N/A,yes,0.032928344,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,677,1,4.375581069,0.375173629,386.431085,235.1203704,3.650042175,yes,#N/A,yes,0.032928344,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,677,1,4.375581069,0.375173629,386.431085,235.1203704,3.650042175,yes,#N/A,yes,0.032928344,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,538,1,4.370023425,0.378111064,739.6247863,-77.075,4.111721232,yes,yes,#N/A,,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,538,1,4.370023425,0.378111064,739.6247863,-77.075,4.111721232,yes,yes,#N/A,,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,538,1,4.370023425,0.378111064,739.6247863,-77.075,4.111721232,yes,yes,#N/A,,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1307,1,2.187067289,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1307,1,2.187067289,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1307,1,2.187067289,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,BCL6,ENSG00000113916,TF,1523,-1,-3.273883394,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,BCL6,ENSG00000113916,TF,1523,-1,-3.273883394,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,BCL6,ENSG00000113916,TF,1523,-1,-3.273883394,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,37,-1,-3.156527058,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,37,-1,-3.156527058,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,37,-1,-3.156527058,0.527614184,413.0269841,337.8371212,3.309975883,yes,yes,yes,0.100724844,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAX,ENSG00000125952,TF,1307,-1,-3.59464472,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAX,ENSG00000125952,TF,1307,-1,-3.59464472,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAX,ENSG00000125952,TF,1307,-1,-3.59464472,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ZNF99,ENSG00000213973,ATF5,ENSG00000169136,TF,538,-1,-11.25774844,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,ARZOXIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ZNF99,ENSG00000213973,ATF5,ENSG00000169136,TF,538,-1,-11.25774844,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,FULVESTRANT,Estrogen receptor antagonist,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ZNF99,ENSG00000213973,ATF5,ENSG00000169136,TF,538,-1,-11.25774844,0.378111064,739.6247863,-77.075,4.111721232,,yes,#N/A,,TOREMIFENE,Estrogen receptor modulator,ESR2,ENSG00000140009,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,53,-1,-5.791696963,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2837,-1,-5.818280702,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,53,-1,-5.791696963,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,53,-1,-5.791696963,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2837,-1,-5.818280702,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2837,-1,-5.818280702,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,53,-1,-5.791696963,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2837,-1,-5.818280702,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,53,-1,-5.791696963,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2837,-1,-5.818280702,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
GPR98,,MAFB,ENSG00000204103,TF,448,-1,-4.531877499,0.400092703,519.4120879,442.4,3.560940401,,yes,#N/A,0.043239717,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,448,-1,-4.531877499,0.400092703,519.4120879,442.4,3.560940401,,yes,#N/A,0.043239717,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,448,-1,-4.531877499,0.400092703,519.4120879,442.4,3.560940401,,yes,#N/A,0.043239717,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,448,-1,-4.531877499,0.400092703,519.4120879,442.4,3.560940401,,yes,#N/A,0.043239717,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,448,-1,-4.531877499,0.400092703,519.4120879,442.4,3.560940401,,yes,#N/A,0.043239717,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,53,-1,-10.18006441,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2837,-1,-10.30114211,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,53,-1,-10.18006441,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,53,-1,-10.18006441,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2837,-1,-10.30114211,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2837,-1,-10.30114211,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,53,-1,-10.18006441,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2837,-1,-10.30114211,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,53,-1,-10.18006441,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2837,-1,-10.30114211,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,53,1,2.212941318,0.613434538,435.5064935,436.7,3.669711001,,yes,yes,0.100724844,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,53,1,2.212941318,0.613434538,435.5064935,436.7,3.669711001,,yes,yes,0.100724844,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,53,1,2.212941318,0.613434538,435.5064935,436.7,3.669711001,,yes,yes,0.100724844,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,53,1,2.212941318,0.613434538,435.5064935,436.7,3.669711001,,yes,yes,0.100724844,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,53,1,2.212941318,0.613434538,435.5064935,436.7,3.669711001,,yes,yes,0.100724844,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,448,1,3.661417824,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,448,1,3.661417824,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,448,1,3.661417824,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,448,1,3.661417824,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,448,1,3.661417824,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,448,-1,-5.861605619,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,53,-1,-6.073019022,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2837,-1,-6.020568732,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,448,-1,-5.861605619,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,448,-1,-5.861605619,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,53,-1,-6.073019022,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,53,-1,-6.073019022,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2837,-1,-6.020568732,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Lenvatinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2837,-1,-6.020568732,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,448,-1,-5.861605619,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,53,-1,-6.073019022,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2837,-1,-6.020568732,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,Nilotinib,#N/A,FGFR1,ENSG00000077782,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,448,-1,-5.861605619,0.400092703,519.4120879,442.4,3.560940401,yes,yes,#N/A,0.043239717,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,53,-1,-6.073019022,0.613434538,435.5064935,436.7,3.669711001,yes,yes,yes,0.100724844,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2837,-1,-6.020568732,0.510215172,448.5353794,260.7777778,3.679350533,yes,#N/A,#N/A,-0.107024401,INFIGRATINIB,Fibroblast growth factor receptor inhibitor,FGFR1,ENSG00000077782,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,FGR,ENSG00000000938,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,560,1,2.237746972,0.87384042,-174.6574074,72.39699248,-2.134323834,,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,560,1,2.98927247,0.87384042,-174.6574074,72.39699248,-2.134323834,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,560,1,6.464929749,0.87384042,-174.6574074,72.39699248,-2.134323834,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,560,-1,-2.191217732,0.87384042,-174.6574074,72.39699248,-2.134323834,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX2,ENSG00000181449,TF,560,-1,-2.758665827,0.87384042,-174.6574074,72.39699248,-2.134323834,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
RYR2,ENSG00000198626,SOX2,ENSG00000181449,TF,560,1,2.832739257,0.87384042,-174.6574074,72.39699248,-2.134323834,,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,FYN,ENSG00000010810,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,DESFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ESZOPICLONE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ETOMIDATE,GABA-A receptor; anion channel positive modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ISOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,MIDAZOLAM,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,PROPOFOL,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,SEVOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1153,1,4.042022654,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,TOPIRAMATE,Carbonic anhydrase II inhibitor,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,DESFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ESZOPICLONE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ETOMIDATE,GABA-A receptor; anion channel positive modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ISOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,MIDAZOLAM,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,PROPOFOL,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,SEVOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,ZNF281,ENSG00000162702,TF,1153,-1,-4.213098501,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,TOPIRAMATE,Carbonic anhydrase II inhibitor,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,DESFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ESZOPICLONE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ETOMIDATE,GABA-A receptor; anion channel positive modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ISOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,MIDAZOLAM,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,PROPOFOL,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,SEVOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1153,1,8.864737973,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,TOPIRAMATE,Carbonic anhydrase II inhibitor,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,DESFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ESZOPICLONE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ETOMIDATE,GABA-A receptor; anion channel positive modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,ISOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,MIDAZOLAM,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,PROPOFOL,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,SEVOFLURANE,GABA-A receptor; anion channel positive allosteric modulator,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1153,1,3.722295568,0.611008975,-404.1248038,-30.25212121,-3.267754199,yes,#N/A,#N/A,-0.09934856,TOPIRAMATE,Carbonic anhydrase II inhibitor,GABRA3,ENSG00000011677,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SATB1,ENSG00000182568,TF,1558,-1,-2.178536735,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1558,1,3.182757101,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PBX1,ENSG00000185630,TF,2588,1,2.724365523,0.523151853,-300.2261905,-27.42857143,-2.547822654,yes,#N/A,#N/A,0.007961587,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,BPTF,ENSG00000171634,TF,3206,1,3.210544209,0.684460067,-280.8597701,-270.5230769,-2.245547701,yes,#N/A,#N/A,-0.197820689,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXJ2,ENSG00000065970,TF,2695,1,4.00627145,0.435941288,-260.7103175,-334.4027778,-2.402219833,yes,#N/A,#N/A,-0.114160794,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1558,1,4.032071338,0.328599874,-276.4173387,43.09821429,-2.138072994,yes,yes,yes,0.009674745,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,PBX1,ENSG00000185630,TF,2588,1,4.50775356,0.523151853,-300.2261905,-27.42857143,-2.547822654,yes,#N/A,#N/A,0.007961587,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,BPTF,ENSG00000171634,TF,3206,1,4.242730294,0.684460067,-280.8597701,-270.5230769,-2.245547701,yes,#N/A,#N/A,-0.197820689,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,GPD2,ENSG00000115159,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX11,ENSG00000176887,TF,1100,1,4.047321808,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX11,ENSG00000176887,TF,1100,1,4.047321808,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,329,1,2.320613788,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,329,1,2.320613788,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX11,ENSG00000176887,TF,1096,1,2.216145581,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX11,ENSG00000176887,TF,1096,1,2.216145581,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-146b,hsa-mir-146b,miRNA,329,-1,2.324127787,-0.407261545,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,#N/A,,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-146b,hsa-mir-146b,miRNA,329,-1,2.324127787,-0.407261545,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,#N/A,,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-146b,hsa-mir-146b,miRNA,1096,-1,2.213559684,-0.433408058,-168.4290541,-208.25,-2.016369893,yes,#N/A,#N/A,,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-146b,hsa-mir-146b,miRNA,1096,-1,2.213559684,-0.433408058,-168.4290541,-208.25,-2.016369893,yes,#N/A,#N/A,,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,SOX11,ENSG00000176887,TF,1100,-1,-3.18870647,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
HYDIN,ENSG00000283022,SOX11,ENSG00000176887,TF,1100,-1,-3.288708933,0.623107666,-95.33928571,-77.98333333,-2.125064135,,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
HYDIN,ENSG00000283022,SOX11,ENSG00000176887,TF,1100,-1,-3.288708933,0.623107666,-95.33928571,-77.98333333,-2.125064135,,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX11,ENSG00000176887,TF,1100,1,7.547043549,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX11,ENSG00000176887,TF,1100,1,7.547043549,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,329,1,4.326224967,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,329,1,4.326224967,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX11,ENSG00000176887,TF,1096,1,4.359236272,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX11,ENSG00000176887,TF,1096,1,4.359236272,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX11,ENSG00000176887,TF,1100,-1,-2.435305334,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX11,ENSG00000176887,TF,1100,-1,-2.435305334,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX11,ENSG00000176887,TF,1100,-1,-3.088393837,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX11,ENSG00000176887,TF,1100,-1,-3.088393837,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX5,ENSG00000134532,TF,329,-1,-4.069467329,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX5,ENSG00000134532,TF,329,-1,-4.069467329,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX11,ENSG00000176887,TF,1096,-1,-4.529927082,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX11,ENSG00000176887,TF,1096,-1,-4.529927082,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX11,ENSG00000176887,TF,1100,1,2.735834221,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX11,ENSG00000176887,TF,1100,1,2.735834221,0.623107666,-95.33928571,-77.98333333,-2.125064135,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,329,1,2.013439285,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,329,1,2.013439285,0.65153363,-213.0917659,-160.8214286,-1.996098609,yes,#N/A,yes,0.017516857,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX11,ENSG00000176887,TF,1096,1,2.105071952,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,PERAMPANEL,Glutamate receptor ionotropic AMPA antagonist,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX11,ENSG00000176887,TF,1096,1,2.105071952,0.708130637,-168.4290541,-208.25,-2.016369893,yes,#N/A,yes,0.005689796,TOPIRAMATE,Carbonic anhydrase II inhibitor,GRIA2,ENSG00000120251,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,HCK,ENSG00000101336,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,FIMEPINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROMIDEPSIN,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,BELINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,PANOBINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VORINOSTAT,Histone deacetylase 2 inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,FIMEPINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROMIDEPSIN,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,BELINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,PANOBINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VORINOSTAT,Histone deacetylase 2 inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,FIMEPINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROMIDEPSIN,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,BELINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,PANOBINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VORINOSTAT,Histone deacetylase 2 inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,FIMEPINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Early Phase 1,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROMIDEPSIN,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 1,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,BELINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,PANOBINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VORINOSTAT,Histone deacetylase 2 inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,FIMEPINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROMIDEPSIN,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,BELINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,PANOBINOSTAT,Histone deacetylase inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,VORINOSTAT,Histone deacetylase 2 inhibitor,HDAC2,ENSG00000196591,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,642,-1,-4.236788298,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,642,-1,-4.236788298,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,642,-1,-4.236788298,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2033,-1,-4.572767571,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2033,-1,-4.572767571,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2033,-1,-4.572767571,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NR2E1,ENSG00000112333,TF,2519,-1,-4.180631771,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NR2E1,ENSG00000112333,TF,2519,-1,-4.180631771,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NR2E1,ENSG00000112333,TF,2519,-1,-4.180631771,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CEBPB,ENSG00000172216,TF,462,-1,-4.774752905,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CEBPB,ENSG00000172216,TF,462,-1,-4.774752905,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CEBPB,ENSG00000172216,TF,462,-1,-4.774752905,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,642,-1,-4.236788298,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2033,-1,-4.572767571,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,NR2E1,ENSG00000112333,TF,2519,-1,-4.180631771,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,CEBPB,ENSG00000172216,TF,462,-1,-4.774752905,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,RORA,ENSG00000069667,TF,2106,-1,-5.726907249,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,hsa-mir-504,hsa-mir-504,miRNA,2106,1,-5.765024776,-0.424987379,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
GPR98,,BACH1,ENSG00000156273,TF,3115,-1,-2.606856849,0.378324426,131.4269619,373.3636364,2.565513614,,#N/A,#N/A,-0.087227094,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BACH1,ENSG00000156273,TF,3115,-1,-2.606856849,0.378324426,131.4269619,373.3636364,2.565513614,,#N/A,#N/A,-0.087227094,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BACH1,ENSG00000156273,TF,3115,-1,-2.606856849,0.378324426,131.4269619,373.3636364,2.565513614,,#N/A,#N/A,-0.087227094,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,BACH1,ENSG00000156273,TF,3115,-1,-2.606856849,0.378324426,131.4269619,373.3636364,2.565513614,,#N/A,#N/A,-0.087227094,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,642,-1,-11.23353208,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,642,-1,-11.23353208,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,642,-1,-11.23353208,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2033,-1,-12.05038404,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2033,-1,-12.05038404,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2033,-1,-12.05038404,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NR2E1,ENSG00000112333,TF,2519,-1,-10.10789611,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NR2E1,ENSG00000112333,TF,2519,-1,-10.10789611,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NR2E1,ENSG00000112333,TF,2519,-1,-10.10789611,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CEBPB,ENSG00000172216,TF,462,-1,-11.41373101,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CEBPB,ENSG00000172216,TF,462,-1,-11.41373101,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CEBPB,ENSG00000172216,TF,462,-1,-11.41373101,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,642,-1,-11.23353208,0.30191969,310.6491228,472.1168831,2.451400767,yes,yes,#N/A,0.161212872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2033,-1,-12.05038404,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,NR2E1,ENSG00000112333,TF,2519,-1,-10.10789611,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,CEBPB,ENSG00000172216,TF,462,-1,-11.41373101,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,RORA,ENSG00000069667,TF,2106,-1,-8.153350511,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,3153,-1,2.245899418,-0.387152949,261.8481105,623.5494505,3.116050384,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,3153,-1,2.245899418,-0.387152949,261.8481105,623.5494505,3.116050384,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,3153,-1,2.245899418,-0.387152949,261.8481105,623.5494505,3.116050384,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2033,-1,2.618172409,-0.395228413,359.1059497,462.3454545,2.891054481,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2033,-1,2.618172409,-0.395228413,359.1059497,462.3454545,2.891054481,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2033,-1,2.618172409,-0.395228413,359.1059497,462.3454545,2.891054481,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1940,-1,2.320989975,-0.380435107,326.7798593,413.8909091,2.656070883,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1940,-1,2.320989975,-0.380435107,326.7798593,413.8909091,2.656070883,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1940,-1,2.320989975,-0.380435107,326.7798593,413.8909091,2.656070883,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,838,-1,2.728349707,-0.368996416,373.0104949,403.2242424,3.115203589,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,838,-1,2.728349707,-0.368996416,373.0104949,403.2242424,3.115203589,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,838,-1,2.728349707,-0.368996416,373.0104949,403.2242424,3.115203589,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,678,-1,2.413381654,-0.383890337,339.4753071,402.7166667,2.615726234,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,678,-1,2.413381654,-0.383890337,339.4753071,402.7166667,2.615726234,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,678,-1,2.413381654,-0.383890337,339.4753071,402.7166667,2.615726234,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2085,-1,2.492321138,-0.392314546,321.5863201,373.4195804,2.846566944,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2085,-1,2.492321138,-0.392314546,321.5863201,373.4195804,2.846566944,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2085,-1,2.492321138,-0.392314546,321.5863201,373.4195804,2.846566944,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,482,-1,3.095385462,-0.386732147,348.4811924,351.6682692,2.700343556,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,482,-1,3.095385462,-0.386732147,348.4811924,351.6682692,2.700343556,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,482,-1,3.095385462,-0.386732147,348.4811924,351.6682692,2.700343556,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1729,-1,2.999172667,-0.37816203,325.0451652,304.484127,2.766370483,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1729,-1,2.999172667,-0.37816203,325.0451652,304.484127,2.766370483,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1729,-1,2.999172667,-0.37816203,325.0451652,304.484127,2.766370483,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,462,-1,2.928325505,-0.355717712,338.1576193,199.2291667,2.928612176,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,462,-1,2.928325505,-0.355717712,338.1576193,199.2291667,2.928612176,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,462,-1,2.928325505,-0.355717712,338.1576193,199.2291667,2.928612176,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,3153,-1,2.245899418,-0.387152949,261.8481105,623.5494505,3.116050384,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2033,-1,2.618172409,-0.395228413,359.1059497,462.3454545,2.891054481,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1940,-1,2.320989975,-0.380435107,326.7798593,413.8909091,2.656070883,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,838,-1,2.728349707,-0.368996416,373.0104949,403.2242424,3.115203589,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,678,-1,2.413381654,-0.383890337,339.4753071,402.7166667,2.615726234,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,2085,-1,2.492321138,-0.392314546,321.5863201,373.4195804,2.846566944,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,482,-1,3.095385462,-0.386732147,348.4811924,351.6682692,2.700343556,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1729,-1,2.999172667,-0.37816203,325.0451652,304.484127,2.766370483,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,462,-1,2.928325505,-0.355717712,338.1576193,199.2291667,2.928612176,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,FOXC1,ENSG00000054598,TF,2033,1,2.732738556,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,FOXC1,ENSG00000054598,TF,2033,1,2.732738556,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,FOXC1,ENSG00000054598,TF,2033,1,2.732738556,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,678,1,2.585082296,0.325833084,339.4753071,402.7166667,2.615726234,yes,#N/A,yes,0.032928344,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,678,1,2.585082296,0.325833084,339.4753071,402.7166667,2.615726234,yes,#N/A,yes,0.032928344,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,678,1,2.585082296,0.325833084,339.4753071,402.7166667,2.615726234,yes,#N/A,yes,0.032928344,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,BACH1,ENSG00000156273,TF,3115,1,2.24461646,0.378324426,131.4269619,373.3636364,2.565513614,yes,#N/A,#N/A,-0.087227094,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,BACH1,ENSG00000156273,TF,3115,1,2.24461646,0.378324426,131.4269619,373.3636364,2.565513614,yes,#N/A,#N/A,-0.087227094,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,BACH1,ENSG00000156273,TF,3115,1,2.24461646,0.378324426,131.4269619,373.3636364,2.565513614,yes,#N/A,#N/A,-0.087227094,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,482,1,2.649342632,0.385471054,348.4811924,351.6682692,2.700343556,yes,yes,#N/A,0.04207445,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,482,1,2.649342632,0.385471054,348.4811924,351.6682692,2.700343556,yes,yes,#N/A,0.04207445,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,482,1,2.649342632,0.385471054,348.4811924,351.6682692,2.700343556,yes,yes,#N/A,0.04207445,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,462,1,3.226007015,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,462,1,3.226007015,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,462,1,3.226007015,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,FOXC1,ENSG00000054598,TF,2033,1,2.732738556,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MTF1,ENSG00000188786,TF,678,1,2.585082296,0.325833084,339.4753071,402.7166667,2.615726234,yes,#N/A,yes,0.032928344,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,BACH1,ENSG00000156273,TF,3115,1,2.24461646,0.378324426,131.4269619,373.3636364,2.565513614,yes,#N/A,#N/A,-0.087227094,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,482,1,2.649342632,0.385471054,348.4811924,351.6682692,2.700343556,yes,yes,#N/A,0.04207445,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,462,1,3.226007015,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
SEMA3C,ENSG00000075223,NR2E1,ENSG00000112333,TF,2519,-1,-2.257683643,0.597949929,353.7915278,201.8666667,2.369132971,,#N/A,#N/A,-0.00778872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR2E1,ENSG00000112333,TF,2519,-1,-2.257683643,0.597949929,353.7915278,201.8666667,2.369132971,,#N/A,#N/A,-0.00778872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR2E1,ENSG00000112333,TF,2519,-1,-2.257683643,0.597949929,353.7915278,201.8666667,2.369132971,,#N/A,#N/A,-0.00778872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR2E1,ENSG00000112333,TF,2519,-1,-2.257683643,0.597949929,353.7915278,201.8666667,2.369132971,,#N/A,#N/A,-0.00778872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
SEMA3C,ENSG00000075223,RORA,ENSG00000069667,TF,2106,-1,-3.697758686,0.368665976,183.3639731,72.05128205,2.683935064,,#N/A,#N/A,-0.02197661,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2033,-1,-4.854175065,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2033,-1,-4.854175065,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2033,-1,-4.854175065,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NR2E1,ENSG00000112333,TF,2519,-1,-5.14556202,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NR2E1,ENSG00000112333,TF,2519,-1,-5.14556202,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NR2E1,ENSG00000112333,TF,2519,-1,-5.14556202,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,462,-1,-4.989226568,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,462,-1,-4.989226568,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,462,-1,-4.989226568,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,DEXCHLORPHENIRAMINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,HISTAMINE,Histamine H1 receptor agonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,ORPHENADRINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2033,-1,-4.854175065,0.437464091,359.1059497,462.3454545,2.891054481,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,NR2E1,ENSG00000112333,TF,2519,-1,-5.14556202,0.597949929,353.7915278,201.8666667,2.369132971,yes,#N/A,#N/A,-0.00778872,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,462,-1,-4.989226568,0.403617678,338.1576193,199.2291667,2.928612176,yes,#N/A,#N/A,-0.045695074,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,RORA,ENSG00000069667,TF,2106,-1,-6.248205922,0.368665976,183.3639731,72.05128205,2.683935064,yes,#N/A,#N/A,-0.02197661,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CYPROHEPTADINE,Histamine H1 receptor antagonist,HRH1,ENSG00000196639,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,450,1,2.703889482,0.867272751,326.5,395.2626263,2.780652732,,yes,#N/A,0.043239717,ALDESLEUKIN,Interleukin-2 receptor agonist,IL2RA,ENSG00000134460,RegulonGene,Phase 2,#N/A
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,450,1,2.703889482,0.867272751,326.5,395.2626263,2.780652732,,yes,#N/A,0.043239717,BASILIXIMAB,Interleukin-2 receptor inhibitor,IL2RA,ENSG00000134460,RegulonGene,Phase 2,#N/A
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SARILUMAB,Interleukin-6 receptor alpha subunit antagonist,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,TOCILIZUMAB,Interleukin-6 receptor alpha subunit inhibitor,IL6R,ENSG00000160712,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,245,-1,-4.139912642,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,RIBAVIRIN,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,245,-1,-4.139912642,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,THIOGUANINE,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,245,-1,-5.997395483,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,RIBAVIRIN,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,245,-1,-5.997395483,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,THIOGUANINE,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,245,1,2.500531788,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,RIBAVIRIN,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,245,1,2.500531788,0.395463171,660.7619048,377.3,3.556010705,yes,#N/A,#N/A,-0.209271379,THIOGUANINE,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1486,-1,2.969062175,-0.47435886,633.8677419,110.35,4.317879409,yes,#N/A,#N/A,,RIBAVIRIN,Inosine-5'-monophosphate dehydrogenase 1 inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1486,-1,2.969062175,-0.47435886,633.8677419,110.35,4.317879409,yes,#N/A,#N/A,,THIOGUANINE,Inosine-5'-monophosphate dehydrogenase (IMPDH) inhibitor,IMPDH1,ENSG00000106348,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,445,-1,-2.189129275,0.8411072,240.0698215,238.3636364,2.040417324,,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,555,1,-3.324662149,-0.553812371,133.9961538,283.9916667,2.151485062,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX11,ENSG00000176887,TF,1095,1,-2.634850089,-0.328058655,194.6217949,-190.8,2.01517344,yes,#N/A,yes,0.005689796,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,555,1,-3.424753544,-0.553812371,133.9961538,283.9916667,2.151485062,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX11,ENSG00000176887,TF,1095,1,-3.022124151,-0.328058655,194.6217949,-190.8,2.01517344,yes,#N/A,yes,0.005689796,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,445,1,2.990821944,0.8411072,240.0698215,238.3636364,2.040417324,,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,293,1,2.820355873,0.456015837,358.9178295,7.111111111,2.33843083,,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,555,-1,3.392877353,-0.553812371,133.9961538,283.9916667,2.151485062,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,445,1,3.629377207,0.8411072,240.0698215,238.3636364,2.040417324,yes,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,293,1,3.105165775,0.456015837,358.9178295,7.111111111,2.33843083,yes,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX11,ENSG00000176887,TF,1095,-1,3.4034442,-0.328058655,194.6217949,-190.8,2.01517344,yes,#N/A,yes,0.005689796,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,293,-1,-1.982768616,0.456015837,358.9178295,7.111111111,2.33843083,yes,yes,#N/A,-0.068933334,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX11,ENSG00000176887,TF,1095,1,-2.39939708,-0.328058655,194.6217949,-190.8,2.01517344,yes,#N/A,yes,0.005689796,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGA4,ENSG00000115232,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1706,-1,-4.000202535,0.453661663,495.1095238,569.3555556,3.593167138,yes,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
DNAH5,ENSG00000039139,SMAD1,ENSG00000170365,TF,1706,1,2.192883842,0.453661663,495.1095238,569.3555556,3.593167138,,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
DNAH5,ENSG00000039139,BCL6,ENSG00000113916,TF,1523,1,2.159430899,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
GPR98,,SMAD1,ENSG00000170365,TF,1706,-1,-4.547191532,0.453661663,495.1095238,569.3555556,3.593167138,,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
GPR98,,MEF2A,ENSG00000068305,TF,481,-1,-4.151455272,0.643249466,446.9744841,352.1784512,3.105274451,,yes,#N/A,0.04207445,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
GPR98,,BCL6,ENSG00000113916,TF,1523,-1,-4.851964641,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
GPR98,,MAFB,ENSG00000204103,TF,438,-1,-4.869968563,0.517683823,500.5265152,159.6259259,3.755955568,,yes,#N/A,0.043239717,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1706,-1,-8.764227556,0.453661663,495.1095238,569.3555556,3.593167138,yes,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,481,1,4.342771626,0.643249466,446.9744841,352.1784512,3.105274451,yes,yes,#N/A,0.04207445,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,438,1,4.363931234,0.517683823,500.5265152,159.6259259,3.755955568,yes,yes,#N/A,0.043239717,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,SMAD1,ENSG00000170365,TF,1706,-1,-3.277387235,0.453661663,495.1095238,569.3555556,3.593167138,,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
SEMA3C,ENSG00000075223,BCL6,ENSG00000113916,TF,1523,-1,-3.273883394,0.341602951,401.1060345,181.8148148,3.211098735,,yes,yes,-0.15023748,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1706,-1,-3.545167951,0.453661663,495.1095238,569.3555556,3.593167138,yes,yes,#N/A,0.003597326,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,438,-1,-3.468401646,0.517683823,500.5265152,159.6259259,3.755955568,yes,yes,#N/A,0.043239717,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB3,ENSG00000259207,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,hsa-mir-551b,hsa-mir-551b,miRNA,3232,1,-3.294185758,-0.344726091,235.1390374,664.6,2.76390219,yes,#N/A,#N/A,,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,hsa-mir-551b,hsa-mir-551b,miRNA,3118,1,-3.418568268,-0.392135484,230.04,458.047619,2.559816147,yes,#N/A,#N/A,,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
GPR98,,TEAD4,ENSG00000197905,TF,1302,-1,-4.658428385,0.320363837,144.8804348,734.2166667,2.241500485,,yes,yes,-0.032367307,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
GPR98,,BACH1,ENSG00000156273,TF,3118,-1,-4.485143062,0.594262478,230.04,458.047619,2.559816147,,#N/A,#N/A,-0.087227094,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,TEAD4,ENSG00000197905,TF,1302,1,2.922315641,0.320363837,144.8804348,734.2166667,2.241500485,yes,yes,yes,-0.032367307,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,BACH1,ENSG00000156273,TF,3118,1,2.85111677,0.594262478,230.04,458.047619,2.559816147,yes,#N/A,#N/A,-0.087227094,CILENGITIDE,Integrin alpha-V/beta-3 antagonist,ITGB5,ENSG00000082781,RegulonGene,Phase 2,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NR1H2,ENSG00000131408,TF,662,-1,-2.924803656,0.326990628,364.1239496,-0.612745098,2.643972246,yes,#N/A,#N/A,-0.117235927,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NR1H2,ENSG00000131408,TF,662,-1,-2.815441518,0.326990628,364.1239496,-0.612745098,2.643972246,yes,#N/A,#N/A,-0.117235927,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NR1H2,ENSG00000131408,TF,662,-1,-2.643496844,0.326990628,364.1239496,-0.612745098,2.643972246,yes,#N/A,#N/A,-0.117235927,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,VEDOLIZUMAB,Integrin alpha-4/beta-7 inhibitor,ITGB7,ENSG00000139626,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,JUN,ENSG00000177606,TF,238,-1,-5.378276635,0.600594784,253.4625,99.53846154,3.265337785,yes,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
DNAH5,ENSG00000039139,JUN,ENSG00000177606,TF,238,1,2.536945782,0.600594784,253.4625,99.53846154,3.265337785,,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,JUN,ENSG00000177606,TF,238,-1,-3.026238353,0.600594784,253.4625,99.53846154,3.265337785,,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,JUN,ENSG00000177606,TF,238,-1,-5.739212114,0.600594784,253.4625,99.53846154,3.265337785,yes,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,JUN,ENSG00000177606,TF,238,1,2.268650509,0.600594784,253.4625,99.53846154,3.265337785,yes,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,JUN,ENSG00000177606,TF,238,-1,-3.773105967,0.600594784,253.4625,99.53846154,3.265337785,,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,796,-1,-5.255752956,0.602668009,480.0013889,189.7111111,2.702038876,yes,#N/A,#N/A,0.069499965,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,JUN,ENSG00000177606,TF,238,-1,-4.449354478,0.600594784,253.4625,99.53846154,3.265337785,yes,#N/A,#N/A,-0.209271379,DIAZOXIDE,"Potassium channel, inwardly rectifying, subfamily J, member 8 opener",KCNJ8,ENSG00000121361,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,DASATINIB,Ephrin type-A receptor 2 inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PAZOPANIB,Macrophage colony stimulating factor receptor inhibitor,LCK,ENSG00000182866,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,NF1,ENSG00000196712,TF,24,1,-2.353939544,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,DASATINIB,Ephrin type-A receptor 2 inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BOSUTINIB,Tyrosine-protein kinase HCK inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,NF1,ENSG00000196712,TF,24,1,-2.338541186,-0.333435561,318.3952703,-19.6031746,2.543790594,yes,#N/A,#N/A,0.117624951,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,BAFETINIB,Tyrosine-protein kinase Lyn inhibitor,LYN,ENSG00000254087,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,557,1,-4.232443064,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,557,1,-4.232443064,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,557,1,-4.232443064,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
GPR98,,MAFB,ENSG00000204103,TF,447,-1,-3.47135405,0.605209156,-229.968254,-493.875,2.985460417,,yes,#N/A,0.043239717,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,447,-1,-3.47135405,0.605209156,-229.968254,-493.875,2.985460417,,yes,#N/A,0.043239717,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,MAFB,ENSG00000204103,TF,447,-1,-3.47135405,0.605209156,-229.968254,-493.875,2.985460417,,yes,#N/A,0.043239717,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,557,1,-7.947673076,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,557,1,-7.947673076,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,557,1,-7.947673076,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,557,-1,2.799177262,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,557,-1,2.799177262,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,447,1,3.116068486,0.605209156,-229.968254,-493.875,2.985460417,yes,yes,#N/A,0.043239717,CABOZANTINIB,Hepatocyte growth factor receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,447,1,3.116068486,0.605209156,-229.968254,-493.875,2.985460417,yes,yes,#N/A,0.043239717,CRIZOTINIB,ALK tyrosine kinase receptor inhibitor,MET,ENSG00000105976,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,557,-1,2.799177262,-0.638252698,185.7558528,-34.91346154,3.160397869,yes,yes,#N/A,-0.076876257,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,447,1,3.116068486,0.605209156,-229.968254,-493.875,2.985460417,yes,yes,#N/A,0.043239717,ONARTUZUMAB,Hepatocyte growth factor receptor antagonist,MET,ENSG00000105976,RegulonGene,Phase 1,#N/A
GPR98,,NFKB1,ENSG00000109320,TF,416,-1,-2.689790982,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,DOXYCYCLINE,Matrix metalloproteinase 7 inhibitor,MMP7,ENSG00000137673,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,416,-1,-6.099677054,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,DOXYCYCLINE,Matrix metalloproteinase 7 inhibitor,MMP7,ENSG00000137673,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,416,1,2.358603796,0.361032258,283.7193676,23.1,2.475822902,,#N/A,yes,-0.032298401,DOXYCYCLINE,Matrix metalloproteinase 7 inhibitor,MMP7,ENSG00000137673,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,416,1,4.46190652,0.361032258,283.7193676,23.1,2.475822902,yes,#N/A,yes,-0.032298401,DOXYCYCLINE,Matrix metalloproteinase 7 inhibitor,MMP7,ENSG00000137673,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LEF1,ENSG00000138795,TF,1640,-1,-3.505281954,0.586474346,229.4620833,344.8611111,2.98730831,yes,yes,#N/A,-0.147069167,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,410,-1,-2.361661402,0.501166697,250.9333333,564.3035714,2.028535393,,#N/A,yes,-0.032298401,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,LEF1,ENSG00000138795,TF,1640,-1,-2.284221206,0.586474346,229.4620833,344.8611111,2.98730831,,yes,#N/A,-0.147069167,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,410,-1,-4.608054224,0.501166697,250.9333333,564.3035714,2.028535393,yes,#N/A,yes,-0.032298401,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,LEF1,ENSG00000138795,TF,1640,-1,-6.871561444,0.586474346,229.4620833,344.8611111,2.98730831,yes,yes,#N/A,-0.147069167,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,LEF1,ENSG00000138795,TF,1640,1,3.393720811,0.586474346,229.4620833,344.8611111,2.98730831,yes,yes,#N/A,-0.147069167,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
PTEN,ENSG00000283094,hsa-mir-328,hsa-mir-328,miRNA,410,-1,2.163270602,-0.433055206,250.9333333,564.3035714,2.028535393,yes,#N/A,#N/A,,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
PTEN,ENSG00000283094,hsa-mir-328,hsa-mir-328,miRNA,1224,-1,2.132688349,-0.363223605,152.0071146,431.1363636,2.601601444,yes,#N/A,#N/A,,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
PTEN,ENSG00000283094,hsa-mir-328,hsa-mir-328,miRNA,1576,-1,2.207449734,-0.430889301,106.2806527,262.7777778,2.466263623,yes,#N/A,#N/A,,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFA4L2,ENSG00000185633,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,47,-1,-6.262646474,0.401128348,208.1628205,-297.6111111,2.014588279,yes,yes,yes,0.100724844,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
CNTNAP2,ENSG00000278728,IRF2,ENSG00000168310,TF,714,-1,-2.362003902,0.585350531,239.6519608,39.89230769,2.361944296,,#N/A,#N/A,-0.082248802,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,47,-1,-6.881739747,0.401128348,208.1628205,-297.6111111,2.014588279,yes,yes,yes,0.100724844,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,IRF2,ENSG00000168310,TF,714,-1,-3.317326072,0.585350531,239.6519608,39.89230769,2.361944296,,#N/A,#N/A,-0.082248802,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,714,-1,-5.088668189,0.585350531,239.6519608,39.89230769,2.361944296,yes,#N/A,#N/A,-0.082248802,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,47,-1,-4.9358644,0.401128348,208.1628205,-297.6111111,2.014588279,yes,yes,yes,0.100724844,METFORMIN,Mitochondrial glycerol-3-phosphate dehydrogenase inhibitor,NDUFC1,ENSG00000109390,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,DEXAMETHASONE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,PREDNISONE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,TRIAMCINOLONE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,BUDESONIDE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,HYDROCORTISONE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,MIFEPRISTONE,Glucocorticoid receptor antagonist,NR3C1,ENSG00000113580,RegulatorGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,PREDNISOLONE,Glucocorticoid receptor agonist,NR3C1,ENSG00000113580,RegulatorGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,FOXC1,ENSG00000054598,TF,2031,-1,-6.124032141,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,405,-1,-7.644356643,0.438395898,302.5435897,293.9666667,3.081648636,yes,#N/A,yes,-0.032298401,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,405,-1,-7.644356643,0.438395898,302.5435897,293.9666667,3.081648636,yes,#N/A,yes,-0.032298401,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,FOXC1,ENSG00000054598,TF,2031,-1,-7.881164458,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,hsa-mir-338,hsa-mir-338,miRNA,1939,-1,2.178853063,-0.437853739,237.0271012,150.8555556,2.864949507,,#N/A,#N/A,,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,NR3C1,ENSG00000113580,TF,837,-1,-4.29063745,0.373622741,239.1776481,199.5464744,2.985972056,,#N/A,yes,-0.092597974,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,439,-1,-6.010206319,0.446212619,275.2397177,143.4923077,3.061868333,yes,yes,#N/A,0.043239717,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,439,-1,-6.010206319,0.446212619,275.2397177,143.4923077,3.061868333,yes,yes,#N/A,0.043239717,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,CARBETOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,FOXC1,ENSG00000054598,TF,2031,-1,-6.191878823,0.337342603,200.3497778,40.96904762,2.732273465,yes,#N/A,#N/A,-0.112566588,OXYTOCIN,Oxytocin receptor agonist,OXTR,ENSG00000180914,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1170,1,2.791241786,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,337,1,2.243461218,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1170,1,2.791241786,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,337,1,2.243461218,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1170,1,2.791241786,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,337,1,2.243461218,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
ATRX,ENSG00000085224,ZNF281,ENSG00000162702,TF,1170,1,2.791241786,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SOX5,ENSG00000134532,TF,337,1,2.243461218,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1170,1,5.821698494,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,337,1,4.597262215,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,POU2F1,ENSG00000143190,TF,1675,1,5.435696178,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1170,1,5.821698494,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,337,1,4.597262215,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
IDH1,ENSG00000138413,POU2F1,ENSG00000143190,TF,1675,1,5.435696178,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1170,1,5.821698494,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,337,1,4.597262215,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,POU2F1,ENSG00000143190,TF,1675,1,5.435696178,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,ZNF281,ENSG00000162702,TF,1170,1,5.821698494,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SOX5,ENSG00000134532,TF,337,1,4.597262215,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,POU2F1,ENSG00000143190,TF,1675,1,5.435696178,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1170,1,2.870012115,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,337,1,3.216375962,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,POU2F1,ENSG00000143190,TF,1675,1,3.182943928,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,NIRAPARIB,Poly [ADP-ribose] polymerase 2 inhibitor,PARP2,ENSG00000129484,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1170,1,2.870012115,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,337,1,3.216375962,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,POU2F1,ENSG00000143190,TF,1675,1,3.182943928,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,OLAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1170,1,2.870012115,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,337,1,3.216375962,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,POU2F1,ENSG00000143190,TF,1675,1,3.182943928,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,RUCAPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 1,#N/A
TP53,ENSG00000141510,ZNF281,ENSG00000162702,TF,1170,1,2.870012115,0.696549726,-281.2515152,233,-2.197886442,yes,#N/A,#N/A,-0.09934856,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SOX5,ENSG00000134532,TF,337,1,3.216375962,0.716152893,-343.7634783,162.9230769,-2.471875491,yes,#N/A,yes,0.017516857,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,POU2F1,ENSG00000143190,TF,1675,1,3.182943928,0.658692831,-274.2105263,91.07954545,-2.191234086,yes,#N/A,yes,0.052469964,VELIPARIB,"PARP 1, 2 and 3 inhibitor",PARP2,ENSG00000129484,RegulonGene,Phase 2,#N/A
PTEN,ENSG00000283094,hsa-mir-296,hsa-mir-296,miRNA,1178,-1,2.192630142,-0.493720703,67.875,-42.66666667,2.110418,yes,#N/A,#N/A,,ROFLUMILAST,Phosphodiesterase 4 inhibitor,PDE4A,ENSG00000065989,RegulonGene,#N/A,AntiCancerPhaseIV
PTEN,ENSG00000283094,hsa-mir-296,hsa-mir-296,miRNA,1178,-1,2.192630142,-0.493720703,67.875,-42.66666667,2.110418,yes,#N/A,#N/A,,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,PDE4A,ENSG00000065989,RegulonGene,Phase 1,#N/A
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,ROFLUMILAST,Phosphodiesterase 4 inhibitor,PDE4A,ENSG00000065989,RegulonGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,PDE4A,ENSG00000065989,RegulonGene,Phase 1,#N/A
TCHH,ENSG00000159450,SREBF2,ENSG00000198911,TF,1178,-1,-3.736290305,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,ROFLUMILAST,Phosphodiesterase 4 inhibitor,PDE4A,ENSG00000065989,RegulonGene,#N/A,AntiCancerPhaseIV
TCHH,ENSG00000159450,SREBF2,ENSG00000198911,TF,1178,-1,-3.736290305,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,PENTOXIFYLLINE,Adenosine A2 receptor antagonist,PDE4A,ENSG00000065989,RegulonGene,Phase 1,#N/A
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1313,1,2.58594412,0.856652566,924.7857143,656.8,2.5551197,yes,#N/A,yes,-0.177842791,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CA,ENSG00000121879,MutationGene,Early Phase 1,#N/A
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1307,1,2.187067289,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CA,ENSG00000121879,MutationGene,Early Phase 1,#N/A
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CA,ENSG00000121879,MutationGene,Early Phase 1,#N/A
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1526,1,2.242427508,0.319923885,352.0901786,60.4,2.711362578,yes,yes,yes,-0.15023748,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CA,ENSG00000121879,MutationGene,Early Phase 1,#N/A
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1313,1,2.58594412,0.856652566,924.7857143,656.8,2.5551197,yes,#N/A,yes,-0.177842791,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CA,ENSG00000121879,MutationGene,Phase 3,#N/A
PIK3CA,ENSG00000121879,MAX,ENSG00000125952,TF,1307,1,2.187067289,0.326974202,417.5794872,284.6,3.074625601,yes,#N/A,yes,-0.177842791,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CA,ENSG00000121879,MutationGene,Phase 3,#N/A
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1523,1,2.146642273,0.341602951,401.1060345,181.8148148,3.211098735,yes,yes,yes,-0.15023748,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CA,ENSG00000121879,MutationGene,Phase 3,#N/A
PIK3CA,ENSG00000121879,BCL6,ENSG00000113916,TF,1526,1,2.242427508,0.319923885,352.0901786,60.4,2.711362578,yes,yes,yes,-0.15023748,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CA,ENSG00000121879,MutationGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,TCF4,ENSG00000196628,TF,734,1,-2.293281098,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF4,ENSG00000196628,TF,734,1,-2.293281098,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
ATRX,ENSG00000085224,TCF4,ENSG00000196628,TF,734,1,-2.293281098,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,TCF4,ENSG00000196628,TF,734,1,-2.270643248,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF4,ENSG00000196628,TF,734,1,-2.270643248,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
IDH1,ENSG00000138413,TCF4,ENSG00000196628,TF,734,1,-2.270643248,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,KLF4,ENSG00000136826,TF,212,1,2.350563794,0.338006127,296.3229942,53.15,2.242015631,yes,#N/A,yes,-0.177556715,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TCF4,ENSG00000196628,TF,734,1,-2.498994021,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,IDELALISIB,PI3-kinase p110-delta subunit inhibitor,PIK3CD,ENSG00000171608,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,TCF4,ENSG00000196628,TF,734,1,-2.498994021,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,FIMEPINOSTAT,Histone deacetylase inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Early Phase 1,#N/A
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,TCF4,ENSG00000196628,TF,734,1,-2.498994021,-0.314810655,336.3777589,87.6245614,2.375269855,yes,#N/A,yes,0.041677824,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,BUPARLISIB,PI3-kinase class I inhibitor,PIK3CD,ENSG00000171608,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,35,-1,-4.183187033,0.600050076,278.2954545,-79.13636364,2.008028895,yes,yes,yes,0.100724844,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,35,-1,-4.183187033,0.600050076,278.2954545,-79.13636364,2.008028895,yes,yes,yes,0.100724844,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,35,-1,-4.117200894,0.600050076,278.2954545,-79.13636364,2.008028895,yes,yes,yes,0.100724844,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,35,-1,-4.117200894,0.600050076,278.2954545,-79.13636364,2.008028895,yes,yes,yes,0.100724844,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,35,1,2.221658037,0.600050076,278.2954545,-79.13636364,2.008028895,,yes,yes,0.100724844,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,35,1,2.221658037,0.600050076,278.2954545,-79.13636364,2.008028895,,yes,yes,0.100724844,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PIOGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROSIGLITAZONE,Peroxisome proliferator-activated receptor gamma agonist,PPARG,ENSG00000132170,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,625,-1,-2.732888044,0.66042547,425.4435171,92.54702381,2.716667272,,#N/A,yes,-0.056906531,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,703,-1,-2.657713764,0.634500637,432.94375,50.00526316,2.432468096,,#N/A,#N/A,-0.082248802,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,444,-1,-2.666043323,0.546786061,463.2232768,-180.9761905,2.590621765,,yes,#N/A,0.043239717,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,40,-1,-2.912809687,0.772397528,444.5970194,103.6409774,2.434599206,yes,yes,yes,0.100724844,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,IRF3,ENSG00000126456,TF,2825,-1,-2.651689294,0.315564573,447.7847199,-86.12669683,2.400805316,yes,#N/A,#N/A,-0.107024401,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,102,-1,-2.673596678,0.369162541,370.1666667,-97.53174603,2.03591351,yes,#N/A,#N/A,-0.198188755,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
ATRX,ENSG00000085224,hsa-mir-92,hsa-mir-92,miRNA,444,1,-2.820748783,-0.305560112,463.2232768,-180.9761905,2.590621765,yes,#N/A,#N/A,,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,40,-1,-3.449868682,0.772397528,444.5970194,103.6409774,2.434599206,yes,yes,yes,0.100724844,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,IRF3,ENSG00000126456,TF,2825,-1,-3.081034138,0.315564573,447.7847199,-86.12669683,2.400805316,yes,#N/A,#N/A,-0.107024401,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,102,-1,-2.80636077,0.369162541,370.1666667,-97.53174603,2.03591351,yes,#N/A,#N/A,-0.198188755,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
IDH1,ENSG00000138413,GTF2IRD1,ENSG00000006704,TF,3303,1,-2.561942929,-0.360459207,520.3919414,-509.6704545,2.539562859,yes,#N/A,#N/A,0.054824522,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,40,1,3.285335689,0.772397528,444.5970194,103.6409774,2.434599206,,yes,yes,0.100724844,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,625,1,3.396824646,0.66042547,425.4435171,92.54702381,2.716667272,,#N/A,yes,-0.056906531,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,444,1,3.0877542,0.546786061,463.2232768,-180.9761905,2.590621765,,yes,#N/A,0.043239717,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
MUC2,ENSG00000278466,hsa-mir-92,hsa-mir-92,miRNA,444,-1,2.17947807,-0.305560112,463.2232768,-180.9761905,2.590621765,,#N/A,#N/A,,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,40,-1,-3.543183602,0.772397528,444.5970194,103.6409774,2.434599206,yes,yes,yes,0.100724844,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,625,-1,-3.297254306,0.66042547,425.4435171,92.54702381,2.716667272,yes,#N/A,yes,-0.056906531,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF9,ENSG00000213928,TF,75,-1,-3.485061106,0.510379518,433.7870614,70.20238095,2.462052162,yes,#N/A,#N/A,-0.040414652,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,703,-1,-3.523598766,0.634500637,432.94375,50.00526316,2.432468096,yes,#N/A,#N/A,-0.082248802,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,IRF3,ENSG00000126456,TF,2825,-1,-3.544530676,0.315564573,447.7847199,-86.12669683,2.400805316,yes,#N/A,#N/A,-0.107024401,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,444,-1,-3.635888423,0.546786061,463.2232768,-180.9761905,2.590621765,yes,yes,#N/A,0.043239717,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
TP53,ENSG00000141510,GTF2IRD1,ENSG00000006704,TF,3303,1,-2.815045909,-0.360459207,520.3919414,-509.6704545,2.539562859,yes,#N/A,#N/A,0.054824522,MARIZOMIB,20S proteosome inhibitor,PSMB10,ENSG00000205220,RegulonGene,Phase 3,#N/A
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,SOX2,ENSG00000181449,TF,549,1,-2.213351702,-0.35575208,332.8600668,98.45416667,2.534978112,,yes,#N/A,-0.076876257,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF2,ENSG00000168310,TF,700,-1,-2.224624352,0.530384164,336.4917719,79.89384921,2.422939142,,#N/A,#N/A,-0.082248802,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX2,ENSG00000181449,TF,549,1,-2.25647884,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX2,ENSG00000181449,TF,549,1,-2.205172173,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX2,ENSG00000181449,TF,549,-1,2.577714787,-0.35575208,332.8600668,98.45416667,2.534978112,yes,yes,#N/A,-0.076876257,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,SULFASALAZINE,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ASPIRIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,CELECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF2,ENSG00000168310,TF,700,-1,-2.526007423,0.530384164,336.4917719,79.89384921,2.422939142,yes,#N/A,#N/A,-0.082248802,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ACETAMINOPHEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DEXKETOPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,DICLOFENAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ETORICOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,FLURBIPROFEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,INDOMETHACIN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,KETOROLAC,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,NAPROXEN,Cyclooxygenase inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,PARECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,ROFECOXIB,Cyclooxygenase-2 inhibitor,PTGS2,ENSG00000073756,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MYBL1,ENSG00000185697,TF,1889,1,3.307806404,0.631273234,-247.5424837,80.725,-2.269416207,yes,#N/A,#N/A,-0.053208317,REGORAFENIB,Discoidin domain-containing receptor 2 inhibitor,RAF1,ENSG00000132155,RegulonGene,Phase 1,AntiCancerPhaseIV
TP53,ENSG00000141510,MYBL1,ENSG00000185697,TF,1889,1,3.307806404,0.631273234,-247.5424837,80.725,-2.269416207,yes,#N/A,#N/A,-0.053208317,SORAFENIB,Serine/threonine-protein kinase RAF inhibitor,RAF1,ENSG00000132155,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SOX4,ENSG00000124766,TF,2158,1,4.320608964,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,E2F3,ENSG00000112242,TF,943,1,4.884845517,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,E2F3,ENSG00000112242,TF,943,1,4.884845517,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,E2F3,ENSG00000112242,TF,943,1,4.884845517,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,E2F3,ENSG00000112242,TF,943,1,4.884845517,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,E2F3,ENSG00000112242,TF,943,1,4.884845517,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
EGFR,ENSG00000146648,E2F3,ENSG00000112242,TF,943,-1,-3.79990008,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SOX4,ENSG00000124766,TF,2158,1,8.802595253,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,E2F3,ENSG00000112242,TF,943,1,9.941010032,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,E2F3,ENSG00000112242,TF,943,1,9.941010032,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,E2F3,ENSG00000112242,TF,943,1,9.941010032,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,E2F3,ENSG00000112242,TF,943,1,9.941010032,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,E2F3,ENSG00000112242,TF,943,1,9.941010032,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX4,ENSG00000124766,TF,2158,-1,-3.763917194,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
RB1,ENSG00000139687,SOX4,ENSG00000124766,TF,2158,-1,-2.810508688,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SOX4,ENSG00000124766,TF,2158,1,4.159930362,0.808748524,-201.1741014,91.25714286,-2.287509564,yes,yes,#N/A,-0.085058244,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,E2F3,ENSG00000112242,TF,943,1,3.862670451,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,LIDOCAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,E2F3,ENSG00000112242,TF,943,1,3.862670451,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ORPHENADRINE,Histamine H1 receptor antagonist,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,E2F3,ENSG00000112242,TF,943,1,3.862670451,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,RILUZOLE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,E2F3,ENSG00000112242,TF,943,1,3.862670451,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,E2F3,ENSG00000112242,TF,943,1,3.862670451,0.647913901,-287.7298174,57.73333333,-2.440188642,yes,#N/A,#N/A,-0.212169935,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN3A,ENSG00000153253,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TAL1,ENSG00000162367,TF,432,-1,2.710301123,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,LIDOCAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TAL1,ENSG00000162367,TF,432,-1,2.710301123,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ORPHENADRINE,Histamine H1 receptor antagonist,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TAL1,ENSG00000162367,TF,432,-1,2.710301123,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,RILUZOLE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TAL1,ENSG00000162367,TF,432,-1,2.710301123,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TAL1,ENSG00000162367,TF,432,-1,2.710301123,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TAL1,ENSG00000162367,TF,432,-1,3.694229497,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,LIDOCAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TAL1,ENSG00000162367,TF,432,-1,3.694229497,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ORPHENADRINE,Histamine H1 receptor antagonist,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TAL1,ENSG00000162367,TF,432,-1,3.694229497,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,RILUZOLE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TAL1,ENSG00000162367,TF,432,-1,3.694229497,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TAL1,ENSG00000162367,TF,432,-1,3.694229497,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TAL1,ENSG00000162367,TF,432,-1,3.769280586,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,LIDOCAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TAL1,ENSG00000162367,TF,432,-1,3.769280586,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ORPHENADRINE,Histamine H1 receptor antagonist,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TAL1,ENSG00000162367,TF,432,-1,3.769280586,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,RILUZOLE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TAL1,ENSG00000162367,TF,432,-1,3.769280586,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,TAL1,ENSG00000162367,TF,432,-1,3.769280586,-0.346417483,-617.7666667,-297.9393939,-2.457740034,yes,yes,yes,0.129286863,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN5A,ENSG00000183873,RegulonGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SP1,ENSG00000185591,TF,1503,-1,-2.560001494,0.317997393,216.0361648,161.4642857,2.750511975,,yes,#N/A,-0.058777177,LIDOCAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SP1,ENSG00000185591,TF,1503,-1,-2.560001494,0.317997393,216.0361648,161.4642857,2.750511975,,yes,#N/A,-0.058777177,ORPHENADRINE,Histamine H1 receptor antagonist,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SP1,ENSG00000185591,TF,1503,-1,-2.560001494,0.317997393,216.0361648,161.4642857,2.750511975,,yes,#N/A,-0.058777177,RILUZOLE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SP1,ENSG00000185591,TF,1503,-1,-2.560001494,0.317997393,216.0361648,161.4642857,2.750511975,,yes,#N/A,-0.058777177,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SP1,ENSG00000185591,TF,1503,-1,-2.560001494,0.317997393,216.0361648,161.4642857,2.750511975,,yes,#N/A,-0.058777177,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,NFKB1,ENSG00000109320,TF,411,-1,-2.431062202,0.849485157,204.1468254,45.56060606,2.242280506,,#N/A,yes,-0.032298401,LIDOCAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,NFKB1,ENSG00000109320,TF,411,-1,-2.431062202,0.849485157,204.1468254,45.56060606,2.242280506,,#N/A,yes,-0.032298401,ORPHENADRINE,Histamine H1 receptor antagonist,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,NFKB1,ENSG00000109320,TF,411,-1,-2.431062202,0.849485157,204.1468254,45.56060606,2.242280506,,#N/A,yes,-0.032298401,RILUZOLE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,NFKB1,ENSG00000109320,TF,411,-1,-2.431062202,0.849485157,204.1468254,45.56060606,2.242280506,,#N/A,yes,-0.032298401,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,NFKB1,ENSG00000109320,TF,411,-1,-2.431062202,0.849485157,204.1468254,45.56060606,2.242280506,,#N/A,yes,-0.032298401,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,LIDOCAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,ORPHENADRINE,Histamine H1 receptor antagonist,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,RILUZOLE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,ROPIVACAINE,Sodium channel alpha subunit blocker,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,TOPIRAMATE,Carbonic anhydrase II inhibitor,SCN9A,ENSG00000169432,MutationGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,14,1,-4.557615519,-0.561605464,461.9833333,614.9375,3.748039545,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,6,1,-4.598228236,-0.742742077,427.2034392,110.2727273,3.07468144,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,THRA,ENSG00000126351,TF,4,1,-2.592200444,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,14,1,-7.183423488,-0.561605464,461.9833333,614.9375,3.748039545,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,6,1,-6.20541669,-0.742742077,427.2034392,110.2727273,3.07468144,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,THRA,ENSG00000126351,TF,4,1,-2.384368228,-0.377760894,433.3660131,91.29747899,2.567828209,yes,yes,#N/A,0.083365205,LEVOTHYROXINE,Thyroid hormone receptor agonist,THRA,ENSG00000126351,RegulatorGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,440,-1,-2.115779834,0.822776892,378.1844554,-61.0625,2.269124307,,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MEF2A,ENSG00000068305,TF,480,-1,-2.222454042,0.494010097,353.2533386,79.89384921,2.333677379,,yes,#N/A,0.04207445,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,440,-1,-2.115779834,0.822776892,378.1844554,-61.0625,2.269124307,,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
ATRX,ENSG00000085224,HLX,ENSG00000136630,TF,652,-1,-2.520929955,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,ATF5,ENSG00000169136,TF,536,-1,-2.204320774,0.316741107,341.9055331,22.15873016,2.715738925,,yes,#N/A,,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,440,1,2.816125744,0.822776892,378.1844554,-61.0625,2.269124307,,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,HLX,ENSG00000136630,TF,652,1,2.993138216,0.560775682,358.4192377,-29.88888889,2.45227828,,yes,#N/A,-0.017328457,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,440,1,2.816125744,0.822776892,378.1844554,-61.0625,2.269124307,,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,MEF2A,ENSG00000068305,TF,480,1,2.450562045,0.494010097,353.2533386,79.89384921,2.333677379,yes,yes,#N/A,0.04207445,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,ATF5,ENSG00000169136,TF,536,1,2.555485767,0.316741107,341.9055331,22.15873016,2.715738925,yes,yes,#N/A,,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
NF1,ENSG00000196712,HLX,ENSG00000136630,TF,652,1,2.736500385,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,440,-1,-2.555968391,0.822776892,378.1844554,-61.0625,2.269124307,yes,yes,#N/A,0.043239717,IMIQUIMOD,Toll-like receptor 7 agonist,TLR7,ENSG00000196664,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,ARID5A,ENSG00000196843,TF,115,-1,-2.421952479,0.43852254,425.1428571,118.6296296,2.255335743,yes,#N/A,#N/A,0.080033004,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,HLX,ENSG00000136630,TF,652,-1,-2.610546847,0.560775682,358.4192377,-29.88888889,2.45227828,yes,yes,#N/A,-0.017328457,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,440,-1,-2.555968391,0.822776892,378.1844554,-61.0625,2.269124307,yes,yes,#N/A,0.043239717,HYDROXYCHLOROQUINE,Toll-like receptor 7 antagonist,TLR7,ENSG00000196664,RegulonGene,Phase 3,AntiCancerPhaseIV
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1563,1,-4.65543183,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,SAGOPILONE,Tubulin stabiliser,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,SATB1,ENSG00000182568,TF,1563,1,-4.65543183,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,VERUBULIN,Tubulin disrupting agent,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1563,1,-5.900007864,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,SAGOPILONE,Tubulin stabiliser,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,SATB1,ENSG00000182568,TF,1563,1,-5.900007864,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,VERUBULIN,Tubulin disrupting agent,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,FOXO3,ENSG00000118689,TF,2290,1,-5.73882123,-0.490527263,284.1511036,214.375,1.984851785,yes,#N/A,yes,0.030141898,SAGOPILONE,Tubulin stabiliser,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,FOXO3,ENSG00000118689,TF,2290,1,-5.73882123,-0.490527263,284.1511036,214.375,1.984851785,yes,#N/A,yes,0.030141898,VERUBULIN,Tubulin disrupting agent,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1563,1,-3.445753202,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,SAGOPILONE,Tubulin stabiliser,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
TP53,ENSG00000141510,SATB1,ENSG00000182568,TF,1563,1,-3.445753202,-0.71963689,397.6764706,431.4,2.045980891,yes,yes,yes,0.009674745,VERUBULIN,Tubulin disrupting agent,TUBA1C,ENSG00000167553,RegulonGene,Phase 2,#N/A
PTEN,ENSG00000283094,hsa-mir-296,hsa-mir-296,miRNA,1178,-1,2.192630142,-0.493720703,67.875,-42.66666667,2.110418,yes,#N/A,#N/A,,SAGOPILONE,Tubulin stabiliser,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
PTEN,ENSG00000283094,hsa-mir-296,hsa-mir-296,miRNA,1178,-1,2.192630142,-0.493720703,67.875,-42.66666667,2.110418,yes,#N/A,#N/A,,VERUBULIN,Tubulin disrupting agent,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,SAGOPILONE,Tubulin stabiliser,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
SCN9A,ENSG00000169432,SREBF2,ENSG00000198911,TF,1178,-1,-2.603859288,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,VERUBULIN,Tubulin disrupting agent,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
TCHH,ENSG00000159450,SREBF2,ENSG00000198911,TF,1178,-1,-3.736290305,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,SAGOPILONE,Tubulin stabiliser,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
TCHH,ENSG00000159450,SREBF2,ENSG00000198911,TF,1178,-1,-3.736290305,0.550231551,67.875,-42.66666667,2.110418,,yes,yes,0.02852884,VERUBULIN,Tubulin disrupting agent,TUBA4A,ENSG00000127824,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CABAZITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,DOCETAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,PACLITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINBLASTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINCRISTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,COLCHICINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,ERIBULIN,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINORELBINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,IXABEPILONE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,SAGOPILONE,Tubulin stabiliser,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
ATRX,ENSG00000085224,PRRX2,ENSG00000167157,TF,3545,-1,-2.746730005,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VERUBULIN,Tubulin disrupting agent,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,CABAZITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,DOCETAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,PACLITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINBLASTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINCRISTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,COLCHICINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,ERIBULIN,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VINORELBINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,IXABEPILONE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,SAGOPILONE,Tubulin stabiliser,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
IDH1,ENSG00000138413,PRRX2,ENSG00000167157,TF,3545,-1,-5.358649753,0.47873139,307.3157895,-609.35,3.678945863,yes,#N/A,#N/A,0.104667031,VERUBULIN,Tubulin disrupting agent,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,CABAZITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,DOCETAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,PACLITAXEL,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,VINBLASTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,VINCRISTINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,COLCHICINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,ERIBULIN,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,VINORELBINE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,IXABEPILONE,Tubulin inhibitor,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,SAGOPILONE,Tubulin stabiliser,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
NF1,ENSG00000196712,SOX15,ENSG00000129194,TF,1485,-1,3.133037039,-0.560895341,29.9047619,-89.33333333,3.010715631,yes,#N/A,#N/A,,VERUBULIN,Tubulin disrupting agent,TUBB6,ENSG00000176014,RegulonGene,Phase 2,#N/A
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAFB,ENSG00000204103,TF,436,-1,-2.172241043,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,IRF8,ENSG00000140968,TF,623,-1,-2.2800512,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPA,ENSG00000245848,TF,290,-1,-2.172328804,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,REL,ENSG00000162924,TF,317,-1,-2.147772694,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,CEBPB,ENSG00000172216,TF,457,-1,-2.196328664,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
AHNAK2,ENSG00000185567,MAF,ENSG00000178573,TF,154,-1,-2.191501875,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,98,-1,-2.175541046,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,STAT3,ENSG00000168610,TF,378,-1,-2.566289742,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,REL,ENSG00000162924,TF,317,-1,-2.480698048,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,CTF1,ENSG00000150281,TF,23,-1,-2.442122163,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,NFIB,ENSG00000147862,TF,0,1,-2.375391584,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,PRDM1,ENSG00000057657,TF,113,-1,-4.131174373,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,LMO2,ENSG00000135363,TF,231,-1,-2.516396575,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,98,-1,-2.195501565,0.49130241,312.5467328,67.51289683,2.499389643,,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,NFKB1,ENSG00000109320,TF,402,-1,-2.225406804,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,PRDM1,ENSG00000057657,TF,113,-1,-2.622549367,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,98,-1,-2.248093013,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,STAT3,ENSG00000168610,TF,378,-1,-2.63844727,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,REL,ENSG00000162924,TF,317,-1,-2.471894639,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,CTF1,ENSG00000150281,TF,23,-1,-2.744662685,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,NFIB,ENSG00000147862,TF,0,1,-2.522357519,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,PRDM1,ENSG00000057657,TF,113,-1,-4.740408509,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,LMO2,ENSG00000135363,TF,231,-1,-2.306972424,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC16,ENSG00000181143,PRDM1,ENSG00000057657,TF,113,-1,-2.217852394,0.618108236,222.7813288,-145.6272727,3.092220849,,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAFB,ENSG00000204103,TF,436,1,2.943336999,0.812814349,381.872549,79.6713352,2.470220159,,yes,#N/A,0.043239717,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF8,ENSG00000140968,TF,623,1,3.093016173,0.744643209,370.3002588,56.47537879,2.688672947,,#N/A,yes,-0.056906531,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT5A,ENSG00000126561,TF,787,1,3.019814499,0.631754842,405.1296453,52.22539683,2.390289227,,#N/A,#N/A,0.069499965,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,IRF1,ENSG00000125347,TF,34,1,2.863266617,0.60606359,341.0974359,50.74810606,2.403942114,,yes,yes,0.100724844,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,STAT3,ENSG00000168610,TF,378,1,2.94398845,0.511500194,388.2571429,48.74810606,2.714444967,,yes,yes,-0.009695219,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPA,ENSG00000245848,TF,290,1,2.947923378,0.704293335,342.0358974,37.64384921,2.286965386,,yes,#N/A,-0.068933334,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,REL,ENSG00000162924,TF,317,1,2.913998413,0.647551105,351.7848485,14.59116809,2.514347047,,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,CEBPB,ENSG00000172216,TF,457,1,2.869876094,0.732438516,353.0517024,-4.406926407,2.36389902,,#N/A,#N/A,-0.045695074,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,ELF1,ENSG00000120690,TF,505,1,2.75840999,0.602234664,343.9324009,-4.406926407,2.302563163,,yes,#N/A,-0.057585056,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,MAF,ENSG00000178573,TF,154,1,3.015666237,0.626308901,336.0028045,-6.347826087,2.539916778,,#N/A,#N/A,-0.116063008,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
MUC17,ENSG00000169876,NFKB1,ENSG00000109320,TF,402,1,2.83206644,0.616066312,356.0760684,-11.82608696,2.446933198,,#N/A,yes,-0.032298401,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,MAFB,ENSG00000204103,TF,436,1,2.425771725,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,98,1,2.574187494,0.49130241,312.5467328,67.51289683,2.499389643,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,IRF8,ENSG00000140968,TF,623,1,2.90631442,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT5A,ENSG00000126561,TF,787,1,2.613402251,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,STAT3,ENSG00000168610,TF,378,1,2.597585499,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPA,ENSG00000245848,TF,290,1,2.404370699,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,REL,ENSG00000162924,TF,317,1,2.751122047,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,CEBPB,ENSG00000172216,TF,457,1,2.430445551,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,ELF1,ENSG00000120690,TF,505,1,2.268816852,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFKB1,ENSG00000109320,TF,402,1,2.489584188,0.616066312,356.0760684,-11.82608696,2.446933198,yes,#N/A,yes,-0.032298401,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,NFIB,ENSG00000147862,TF,0,-1,2.492709698,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,PRDM1,ENSG00000057657,TF,113,1,2.695801819,0.618108236,222.7813288,-145.6272727,3.092220849,yes,#N/A,#N/A,-0.198188755,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
NF1,ENSG00000196712,LMO2,ENSG00000135363,TF,231,1,2.227967106,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAFB,ENSG00000204103,TF,436,-1,-2.5274087,0.812814349,381.872549,79.6713352,2.470220159,yes,yes,#N/A,0.043239717,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF8,ENSG00000140968,TF,623,-1,-2.61507796,0.744643209,370.3002588,56.47537879,2.688672947,yes,#N/A,yes,-0.056906531,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT5A,ENSG00000126561,TF,787,-1,-2.684596666,0.631754842,405.1296453,52.22539683,2.390289227,yes,#N/A,#N/A,0.069499965,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,34,-1,-2.494837325,0.60606359,341.0974359,50.74810606,2.403942114,yes,yes,yes,0.100724844,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,STAT3,ENSG00000168610,TF,378,-1,-2.774021,0.511500194,388.2571429,48.74810606,2.714444967,yes,yes,yes,-0.009695219,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPA,ENSG00000245848,TF,290,-1,-2.51682908,0.704293335,342.0358974,37.64384921,2.286965386,yes,yes,#N/A,-0.068933334,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,REL,ENSG00000162924,TF,317,-1,-2.489513089,0.647551105,351.7848485,14.59116809,2.514347047,yes,#N/A,#N/A,-0.016762885,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CEBPB,ENSG00000172216,TF,457,-1,-2.638430282,0.732438516,353.0517024,-4.406926407,2.36389902,yes,#N/A,#N/A,-0.045695074,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,ELF1,ENSG00000120690,TF,505,-1,-2.511669866,0.602234664,343.9324009,-4.406926407,2.302563163,yes,yes,#N/A,-0.057585056,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,MAF,ENSG00000178573,TF,154,-1,-2.628142723,0.626308901,336.0028045,-6.347826087,2.539916778,yes,#N/A,#N/A,-0.116063008,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,CTF1,ENSG00000150281,TF,23,-1,-2.80744841,0.309729292,220.1824009,-44.80830281,2.322423627,yes,#N/A,#N/A,-0.335254042,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,NFIB,ENSG00000147862,TF,0,1,-2.706090372,-0.346779171,278.1590636,-76.36666667,2.376011197,yes,#N/A,yes,0.021106578,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ALFACALCIDOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCIFEDIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CALCITRIOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,CHOLECALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,ERGOCALCIFEROL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,LMO2,ENSG00000135363,TF,231,-1,-2.690461175,0.31866658,342.5460705,-155.4848485,2.478078779,yes,#N/A,#N/A,-0.048143139,PARICALCITOL,Vitamin D receptor agonist,VDR,ENSG00000111424,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,42,-1,-3.881899995,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,646,-1,-3.82507909,0.524746076,350.5702341,414.4333333,2.341670777,yes,yes,#N/A,0.161212872,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1709,-1,-3.017583829,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
ATRX,ENSG00000085224,IRF1,ENSG00000125347,TF,42,-1,-3.881899995,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,TCF3,ENSG00000071564,TF,646,-1,-3.82507909,0.524746076,350.5702341,414.4333333,2.341670777,yes,yes,#N/A,0.161212872,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SMAD1,ENSG00000170365,TF,1709,-1,-3.017583829,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
DNAH5,ENSG00000039139,SMAD1,ENSG00000170365,TF,1709,1,2.160883898,0.695409121,162.3107143,327.6517857,2.162665865,,yes,#N/A,0.003597326,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
DNAH5,ENSG00000039139,SMAD1,ENSG00000170365,TF,1709,1,2.160883898,0.695409121,162.3107143,327.6517857,2.162665865,,yes,#N/A,0.003597326,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1709,-1,-3.034975972,0.695409121,162.3107143,327.6517857,2.162665865,,yes,#N/A,0.003597326,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,HIF1A,ENSG00000100644,TF,2946,-1,-2.39942614,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
GPR98,,SMAD1,ENSG00000170365,TF,1709,-1,-3.034975972,0.695409121,162.3107143,327.6517857,2.162665865,,yes,#N/A,0.003597326,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
GPR98,,HIF1A,ENSG00000100644,TF,2946,-1,-2.39942614,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,42,-1,-7.585212207,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,646,-1,-7.189779608,0.524746076,350.5702341,414.4333333,2.341670777,yes,yes,#N/A,0.161212872,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1709,-1,-6.419579675,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,HIF1A,ENSG00000100644,TF,2946,-1,-5.339901843,0.623091248,311.6944444,-120.6590909,2.493054603,yes,yes,#N/A,0.05107959,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
IDH1,ENSG00000138413,IRF1,ENSG00000125347,TF,42,-1,-7.585212207,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,TCF3,ENSG00000071564,TF,646,-1,-7.189779608,0.524746076,350.5702341,414.4333333,2.341670777,yes,yes,#N/A,0.161212872,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,SMAD1,ENSG00000170365,TF,1709,-1,-6.419579675,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
IDH1,ENSG00000138413,HIF1A,ENSG00000100644,TF,2946,-1,-5.339901843,0.623091248,311.6944444,-120.6590909,2.493054603,yes,yes,#N/A,0.05107959,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
LRP2,ENSG00000081479,HIF1A,ENSG00000100644,TF,2946,1,2.738755406,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
LRP2,ENSG00000081479,HIF1A,ENSG00000100644,TF,2946,1,2.738755406,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,MAFG,ENSG00000197063,TF,1774,-1,-2.9275437,0.35362985,502.7159459,-10.9375,2.231525416,,yes,#N/A,0.060839113,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,HIF1A,ENSG00000100644,TF,2946,-1,-2.356501045,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,MAFG,ENSG00000197063,TF,1774,-1,-2.9275437,0.35362985,502.7159459,-10.9375,2.231525416,,yes,#N/A,0.060839113,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
SEMA3C,ENSG00000075223,HIF1A,ENSG00000100644,TF,2946,-1,-2.356501045,0.623091248,311.6944444,-120.6590909,2.493054603,,yes,#N/A,0.05107959,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,42,-1,-3.480691856,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1709,-1,-2.973257281,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,HIF1A,ENSG00000100644,TF,2946,-1,-3.660316008,0.623091248,311.6944444,-120.6590909,2.493054603,yes,yes,#N/A,0.05107959,BEVACIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,Phase 2,AntiCancerPhaseIV
TP53,ENSG00000141510,IRF1,ENSG00000125347,TF,42,-1,-3.480691856,0.312690555,305.4829193,441.95,2.3662803,yes,yes,yes,0.100724844,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,SMAD1,ENSG00000170365,TF,1709,-1,-2.973257281,0.695409121,162.3107143,327.6517857,2.162665865,yes,yes,#N/A,0.003597326,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
TP53,ENSG00000141510,HIF1A,ENSG00000100644,TF,2946,-1,-3.660316008,0.623091248,311.6944444,-120.6590909,2.493054603,yes,yes,#N/A,0.05107959,RANIBIZUMAB,Vascular endothelial growth factor A inhibitor,VEGFA,ENSG00000112715,RegulonGene,#N/A,AntiCancerPhaseIV
ATRX,ENSG00000085224,SRF,ENSG00000112658,TF,1838,-1,-4.127898199,0.329871213,337.6166667,521.6111111,2.123177056,yes,#N/A,yes,-0.008434734,ADAVOSERTIB,Serine/threonine-protein kinase WEE1 inhibitor,WEE1,ENSG00000166483,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,SRF,ENSG00000112658,TF,1838,-1,-7.597149708,0.329871213,337.6166667,521.6111111,2.123177056,yes,#N/A,yes,-0.008434734,ADAVOSERTIB,Serine/threonine-protein kinase WEE1 inhibitor,WEE1,ENSG00000166483,RegulonGene,Phase 1,#N/A
IDH1,ENSG00000138413,NFKB1,ENSG00000109320,TF,424,-1,-8.864262572,0.612774245,183.3766234,403.875,2.546992517,yes,#N/A,yes,-0.032298401,ADAVOSERTIB,Serine/threonine-protein kinase WEE1 inhibitor,WEE1,ENSG00000166483,RegulonGene,Phase 1,#N/A
LRP2,ENSG00000081479,hsa-mir-138,hsa-mir-138,miRNA,424,-1,4.396183239,-0.363984026,183.3766234,403.875,2.546992517,,#N/A,#N/A,,ADAVOSERTIB,Serine/threonine-protein kinase WEE1 inhibitor,WEE1,ENSG00000166483,RegulonGene,Phase 1,#N/A
MUC17,ENSG00000169876,hsa-mir-138,hsa-mir-138,miRNA,424,1,-2.128767736,-0.363984026,183.3766234,403.875,2.546992517,,#N/A,#N/A,,ADAVOSERTIB,Serine/threonine-protein kinase WEE1 inhibitor,WEE1,ENSG00000166483,RegulonGene,Phase 1,#N/A